In the BioHarmony Drug Report Database

"Preview" Icon

Sarilumab

Kevzara (sarilumab) is an antibody pharmaceutical. Sarilumab was first approved as Kevzara on 2017-05-22. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against interleukin-6 receptor subunit alpha.

 

Trade Name

 

Kevzara
 

Common Name

 

sarilumab
 

ChEMBL ID

 

CHEMBL2108730
 

Indication

 

rheumatoid arthritis
 

Drug Class

 

Monoclonal antibodies: fully human, immunomodulating

Image (chem structure or protein)

Sarilumab structure rendering